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1134-25 B-Type Natriuretic Peptide Predicts Lefi Ventricular 
Response to Surgery in Patients With Severe Mitral 
Regurgitation in Asymptomatic Patients With Preserved 
Left Ventricular Function 
Conlusions: NT-proBNP was closely linked to severity of aortic stenosis and therefor 
may be usefull for therapeutical decision making. 
1134-23 Is Mitral Regurgitation in Congestive Heart Failure Truly 
Functional? Evidence for Significant Biochemical 
Changes in the Valvular Extracellular Matrix 
Kathwn J. Grande-Allen. Richard W. Troughton, Allen G. Borowski, Penny L. 
Houghtaling, Nicholas R. DiPaola, Chnstine S. Moravec, Ivan Vesely. Bnan P. Griffin, 
The Cleveland Clinic Foundation, Cleveland, OH 
Background: Mitral regurgitation (MR) is a complication for many patients with congestive 
heart failure (CHF). This MR was previously thought to be functional, due to alterations in 
the cardiac geometty rather than in the valvular microstructure. In contrast, we hypothe- 
size that the geometric alterations found in CHF might be associated with biochemical 
changes in the extracellular matrix of the mitral valve. 
Methods: Mitral valves were obtained post transplant from hearts with CHF (20 dilated 
cardiomyopathy, 14 ischemlc. 3 other); all patients had undergone recent echocardio- 
graphy. Left ventricular (LV) collagen and valvular DNA, collagen, glycosaminoglycan 
(GAG), and water content were measured, normalized to tissue weight, and compared 
with autopsy controls (n=12). .Valvular and cardiac chamber dimensions and functional 
parameters were compared with biochemical parameters using a repeated measures 
generalized linear model. 
Results: The mitral leaflets in CHF had 88% more DNA, 18% more GAGS, and 6% more 
collagen than normal (p<O.O5). Mitral chordae in CHF had 83% more DNA, 42% more 
GAGS, and 8% less water (pcO.05). The elevated leaflet collagen concentration was sig- 
nificantly associated with increased anterior leaflet length and LV dimensions, and 
slightly associated with MR grade (p=O.O6). Increased leaflet DNA, an indicator of cellu- 
larity, was associated with anterior leaflet thickening (p=O.O02) and MR grade (p=O.Ol). 
Elevated leaflet GAGS were associated with left atrial diameter (p=O.O02) and alterations 
in early and late diastolic flow (~~0.05). Chordal collagen, cellularity, and water concen- 
trations were similarly associated with annular and ventricular dimensions as well as LV 
collagen concentration (pcO.04). 
Conclusion: Mitral leaflets and chordae in CHF have significant biochemical differences 
from autopsy controls. These changes in the valvular extracellular matrix occw in propor- 
tion to the alterations in cardiac dimensions that accompany CHF. Our biochemical find- 
Ing of leaflet and chordal remodeling suggests that MR in patients with CHF may not be 
purely functional, and that these mitral valves from failing hearts should not be consid- 
ered “normal.” 
1134-24 Neurohormonal Activation Is Associated With Left 
Ventricular Remodeling in Chronic Asymptomatic Mitral 
Regurgitation and Normal Lefl Ventricular Ejection 
Fraction 
Min Laurence M. Demers. Joseph Gascho, Hua Yang, John Boehmer, Benjamin C. 
Sun, Sanjay M. Mehta, Sanjay M. Mehta, Walter Pac. William Davidson, Jr., Hershey 
Medical Center, Hershey, PA 
Background: Neurohormones are elevated in patients with chronic symptomatic mitral 
regurgitation (MR) and/or left ventricular (LV) dysfunction. There is little data regarding 
neurohormonal activation in asymptomatic MR with normal resting and exercise LV func- 
tion. 
Methods: We report our initial results of a prospective study. A total of 14 normal sub- 
jects and 7 asymptomatic MR patients were enrolled. Patients had at least 3+ MR, regur- 
gitant orifice area of 0.43+0.12cm2 and resting LV ejection fraction (LVEF) of 65+5.5%. 
Plasma epinephrine, norepinephrine. renin activity and N-terminal brain natriuretic pep- 
tide (N-BNP) were measured. Resting and stress exercise echocardiography were per- 
formed. LVEF, end-diastolic diameter (LVEDD). volume, end-systolic diameter and 
volume were measured. Exercise capacity was expressed as metabolic equivalents. 
Resells: Although MR patients presented with normal resting LVEF and normal exercise 
response (increased LVEF, decreased LV end-systolic diameter with excellent exercise 
capacity-metabolic equivalents, 12*1.7), neurohormones were elevated, especially N- 
BNP (table). Significant LV remodeling was seen in the MR group with increased resting 
and post-exercise LV diameters and volumes. Conclusions: Neurohormones, especially 
N-BNP, are elevated in asymptomatic MR patients with apparently normal resting and 
exercise LV function, but dilated LV. Neurohormonal activation may indicate ongoing LV 
remodeling due to volume overload. 
W.H. Wilson Tang, Richard W. Trouahton, Deborah A. Agler, Kathy Morris, Gary S. 
Francis, Jianxin Cain. Brian P. Griffin, The Cleveland Clinic Foundation. Cleveland, OH 
Background: BNP has been validated as marker of cardiac function and prognosis in a 
variety of settings. To date, the relationship of pre- and post-op BNP to cardiac structure 
and function in asymptomatic patients with severe mitral regurgitation (MR) has not been 
well defined. Methods: We prospectively studied 22 consecutive asymptomatic patients 
(mean age 56 +13 yrs) with severe MR and LV ejection fraction (EF) =55% referred for 
mitral valve surgery. Patients undenvent pre- and post-op 2D echo evaluation, with con- 
current sampling of BNP (Biosite). LV volumes and EF were calculated by biplane Simp- 
son’s method. Cardiac dysfunction was defined as EF ~50%. Results: Mean pre-op data 
included: regurgitant orifice area = 0.88 4.4 cn?, EF = 61 *6%. LVEDV = 177 i44 ml, 
LVESV = 69 +23 ml. BNP increased acutely from 92 *73 pg/ml to 314 +200 pg/ml follow- 
ing surgery. Pre-op IogBNP correlated significantly with pre-op LA volume (r=0.49, 
p=O.O4), post-op LVESV (r= 0.50, ~~0.04) and post-op EF (r= 0.51, p=O.O3). but not with 
other echo measures. Pre-op BNP was higher in patients who developed post-op cardiac 
dysfunction (141 *85 pglml vs 57 251 pg/ml. p=O.O3). A pre-op BNP of 50 pg/ml had a 
sensitivity of 83%, specificity of 60%, and negative predictive value of 91% for prediction 
of a post-op cardiac dysfunction (r&0.8). Conclusion: Pre-op plasma BNP correlates 
significantly with post-op EF and LVESV in our study population. A pre-op plasma BNP 
below 50 pg/ml maybe useful in excluding the likelihood of post-op cardiac dysfunction. 
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1134-26 Serum B-Type Natriuretic Peptide in Patients With 
Chronic Mitral Regurgitation Is Not Elevated 
Micah J. Eimer, Deborah Ekery. Vera Rigolin, Robert 0. Bonow, William Cotts, 
Northwestern University Medical School, Chicago, IL 
Background: Chronic mitral regurgitation (MR) imposes a progressive hemodynamic 
burden upon the left ventricle (LV). Management is based on symptoms and LV size and 
function. To determine if B-Type natriuretic peptide (BNP), a hormone secreted by ven- 
tricular myocytes under strain, may be a useful marker of ventricular deterforation, we 
measured BNP levels I” patients with chronic MR. 
Methods: We studied 9 patients with moderate to severe MR and a range of symptoms 
(mean age 45 216.6) and five normal control subjects (mean age 42.2 211.1) by 2D 
echocardiography with Doppler. LV ejection fraction (EF), LV end diastolic volume 
(EDV), end systolic volume (ESV), and LV mass index (LVMI) were measured and sever- 
ity of MR was assessed semiquantitatively using color Doppler. Patients were excluded if 
they had any other valve lesion. BNP levels were measured by the Shionogi assay. 
Results: Patients and controls did not dtffer in age and had similar EF (63+12 vs 66+9%. 
p=ns). Seven of the 9 patients had severe MR and 6 had dyspnea, of whom 2 underwent 
valve surgery within 6 months. Compared to controls, the MR patients had significantly 
higher LVMI (109230 YS 72+15 s/m*. pz.02). ESV (53125 vs 2726 ml, p=.O2) and EDV 
(132H2 vs 84223 ml, pz.04). However, there was no significant difference in serum BNP 
levels (1 k_s vs 6+4 pg/ml, p=O.20) between the two groups, and BNP did not relate to 
severity of MR or to symptoms. 
Conclusion: These flndings suggest that chronic MR is not associated with elevated lev- 
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els of B-Type natriuretic peptide despite significantly increased LV mass and volumes, 
even in patients with symptoms. Therefore, BNP may not be a useful marker in the man- 
agement and evaluation of patients with chronic MR 
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841-I The Effective Regurgitant Orifice Area Is Predictive of 
Survival in Patients With Organic Mitral Regurgitation 
Maurice L. Enriauez-Sarano, A. Jamil Tajrk, David Messika-Zeitoun, Jean-Francois 
Avierinos, Michael Bellamy, Christophe Triboullloy, Mayo Clinic, Rochester, MN 
Background: Quantitation of mitral regurgitation (MR) is possible using Doppler- 
Echocardiography and allows measurement of the Effective Regurgitant orifice (ERO) 
area and of the Regurgitant volume (RVol). However, the implications of these measure- 
ments regarding survival after diagnosis are unknown because no long-term study out- 
come study has yet been conducted. 
Methods: We prospectively enrolled 456 patients with MR due to organic mitral lessons 
(mitral prolapse in 360 or 79%) in whom quantitatlon of MR was obtained at baseline by 
at least 2 independent methods. The end-points analyzed were survival under conserva- 
tive management and the combined end-point of death or mitral surgery. 
Results: At diagnosis, age was 64+14 years and 61% were male, ERO was 41i26 mm2 
(range 2 to 180 mm2) and RVol was 65+40 ml/beat (range 3 to 227). The left ventnculat 
end-diastolic volume was enlarged at 107+26 mUm2 and the ejection fraction was nor- 
mal at 69+9%. The 5.year rates of mortality under conservative management and of sur- 
gery or death were 24+3% and 66+3%. Both ERO and RVol were unwariately predictive 
of these end-points (PcO.001) but in multivariate analysis adjusting for age, sex, func- 
tional class and ejection fraction, only ERO was predictive of suwival (RR 1.22 [1.06- 
1.381 par 10 mm2 increase, P=O.O05). ERO was also independently predictive of death 
or mitral surgery (RR 1.41 [1.29-l ,521 per IO mm2 increase, P-zO.001). 5 years after diag- 
nosis, for patients with ER0<20, 20-30 and X30 mm3. mortality under conservative man- 
agement was 9+3%. 31 +lO% and 49*6%, respectively and death or mitral surgery 
(excluding patients operated within 3 months of diagnosis) was 14*4%, 55*9% and 
63+4%. respectively (both P<O.OOl). 
Conclusion: The present study demonstrates for the first time in patients with organic 
MR. l-the strong outcome implications of quantitative measures of degree of MR, P-the 
preeminent Independent prognostic value for surwal of ERO area. which 3.allows to 
stratify patients into groups at low-, medium- and high-risk. Hence. measurement of ERO 
area of MR is an essential tool in management of patients with orgamc MR. 
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841-2 Brain Natriuretic Peptide Predicts Severity of Aortic 
Stenosis 
Johann Auer, Thomas Weber, Robert Berent, Elisabeth Lassnig. Josef Seier, Bernd 
Eber, General Hospital Wels, Wels, Austria 
Background: Bratn natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) consti- 
tute a cardiac hormone system mediating natriuresis, diuresis, and vasodilation. 
Whereas ANP is secreted mainly from cardiac atria, BNP is produced to a larger extent in 
ventricles and has been shown to correlate with end-systolic wall stress in patients with 
aorilc stenosis (AS). Echocardiography with doppler examination of the aortic valve pro- 
vides a vary accurate assessment of the trans.valvular aortic pressure gradient (TVPG) 
and is used to monitor progression of AS. This study evaluated circulating BNP as a 
marker of left ventricular hyperirophy and atrial pressure increase in patients with AS. 
Patients and Methods: We westigated the serum concentrations of BNP by radioimmu- 
noassay in 69 AS patients (35 males, mean age 70,9 years; range 37-90; mean TVPG 
determlned by echocardlography 45,2 mmHg (+I- 20.6). calculated mean aortic valve 
area (AVA) (assessed invasively) 0,65 cm2 (+/- 0.3). TVPG were correlated to the AVA 
(r=O.54, P=O.OOl). Results are expressed as mean (+/- standard deviation), correlations 
were tested by Spearman-rang test and comparisons between group were tested by the 
Mann-Whitney test. 
Results: BNP levels were slgnlficantly higher I” AS patients with AVA less than 1 cm2 
(2558,5 pg/ml; +I- 2555,6) when compared with the patients with AVA more than 1 cm2 
(1567,4 pglml (+/- 2447,9) P=O,O49). Moreover, BNP levels were increased in AS 
patients with TVPG of 50 (60.5 +/- 10,3) mmHg or more (4351,4 pgiml; +/- 4699,5) in 
comparison to patients with TVPG less than 50 (29,9 +/- 16,6) mmHg (1373,6 pg/ml: +/- 
2176.8, P=O,O4). BNP levels ware correlated to the TVPG and AVA (w0.43 and wO.52, 
P<O.OOl), respectively. 
Conclusion: These results suggest BNP levels rncrease I” relation to the NPG and AVA. 
BNP measurement could potentially be used to monitor progression of disease non-inva- 
sively. This marker may also be useful to identify the optimum time for surgery in AS. 
JACC March 19,2003 
9:00 a.m. 
841-3 Mitral Annular Calcification, Aortic Sclerosis, and 
Incident Stroke in American Indians Free of Clinical 
Cardiovascular Disease 
Jorae R. Kizer, David 0. Wiebers, Jack P. Whisnant, James M. Galloway, Thomas K. 
Welty, Elisa T. Lee, Lyle Best, Mary J. Roman. Richard B. Devereux, Weill Medical 
College of Cornell University, New York, NY, Mayo Clinic, Rochester, MN 
While mitral annular calcification (MAC) 8 aortic sElerosis have been reported to be risk 
factors for cerebrovascular events, their relative prognostic significance Independent of 
other echo predictors is uncertain. We investigated the predictive value of MAC & aortic 
sclerosis for lncldent stroke while accounting for other proven echo predictors. Our 
cohort comprised American Indians in the Strong Heart Study having echo in 1993.95. 
Exclusion criteria: coronaty/valvular disease (aortic stenosis); prior stroke; atrlal flbrilla- 
tion; ejection fraction -< 35%; segmental wall motion abnormality. Follow-up was obtained 
through 12/99. N = 2659. Age = 56 y, women = 64%. hypertension = 54%, diabetes = 
47%. cholesterol/HDL = 4.7, body-mass index = 31 kg/m2, smoker = 31%, renal insuff- 
ciency = 2.3%, MAC = lo%, aortic sclerosis = 8% left atrial index = 2.2 cm/m, LV mass 
index = 40 g/m2 7. lncldent strokes = 60. MAC, but not aortic sclerosis, was a significant 
univariable predictor of stroke (Figure). In Cox models adjusting for all above factors, 
MAC emerged as an independent predictor of stroke (RR 2.2, P = 0.026). Aortic sclerosis 
was not predictive whether or not MAC was considered. Our findings demonstrate MAC 
to be a strong predictor of stroke independent of other echo risk factors, & are in line with 
other studies showing that aortic sclerosis is not independently predictive of cerebral 
events. In patients without overt cardiovascular disease, the isolated presence of MAC 
warrants aggressive primary prevention. 
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841-4 Does Aortic Valve Sclerosis Predict Cardiovascular 
Events Independently of Albuminuria in Hypertension? 
A LIFE Study 
Michael H. Olsen Kristian Wachtell, Jonathan N. Bella. Vittorio Palmieri, Eva Gerdts, 
Markku S. Nieminen. Gunnar Smith. Blbrn DahlBf. Hans Ibsen. Richard B. Devereux. , 
Glostrup University Hospital, Copenhagen, Denmark, The Weill Medical College of 
Cornell University, New York, NY 
Background: Aortic valve (AV) sclerosis and albuminuria are strong cardiovascular risk 
factors and they are both thought to be markers of atherosclerosis. In the LIFE study we 
investigated the predictive value of AV sclerosis for the composite endpoint (CEP) of car- 
diovascular death, non-fatal stroke or non-fatal myocardlal Infarctron correcting for urine 
albuminlcreatinine ratio (UACR) and other cardiovascular risk factors. 
Methods: After two weeks of placebo treatment, clinical, laboratory, and echocardio- 
graphic variables were assessed in 960 hypertensive patients from the LIFE Echo sub- 
study, aged 55-60 (mean 66*7) years, with electrocardiographic LV hypertrophy, and 
without known AV stenosis. Morning urine albumin and creatinine were measured, and 
urine albumin-creatinine ratio (UACR) was calculated. Macro- and microalbumlnuria 
were defined as UACRa5 and 3.5cUACR<35, respectively. AV sclerosis was defined as 
valve thickening or calcification. 15 patients with mild AV stenosis were excluded. 
Results: AV sclerosis was found in 366 patients and was associated with higher inci- 
dence of CEP (15.5% vs. 6.3%“). Micro- and macroalbuminuria were found in 143 
(17.1%) and 23 (2.6%) patients, respectively, and both were associated with higher Inci- 
dence of CEP (15% and 22% vs. 9.9%‘). The incidence of CEP increased progressively 
with micro- and macroalbummuria in oatients without AV sclerosis II 1.4% and 15.4% vs. 
8.3%‘) as well as in patients with AV sclerosis (19.2% and 30% vs. 12.7%‘). In Cox 
reoression analvses AV sclerosis was oredlctlve of the CEP [odds ratio IORl = 1.6’) inde- 
pendent of log UACR (I .5’); male gender (2.1”); and history of peripheral vascular dis- 
ease (2.5-I diabetes mellitus (2.3”) or cerebral vascular disease (2.4.‘). P<O.O5. 
